Neon Bloom, Inc. (NBCO)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -632.4 Thousand USD | 2.43% |
| 2022 | -428.62 Thousand USD | 68.95% |
| 2021 | -1.28 Million USD | -1381.39% |
| 2020 | -60.84 Thousand USD | 99.58% |
| 2019 | -20.52 Million USD | -4515.46% |
| 2018 | -444.69 Thousand USD | 17.14% |
| 2017 | -536.67 Thousand USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2010 | -1.49 Million USD | -823.51% |
| 2009 | -134.83 Thousand USD | -136.76% |
| 2008 | 437.4 Thousand USD | 137.14% |
| 2007 | -1.17 Million USD | -2640.28% |
| 2006 | -49.08 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -12.53 Thousand USD | 95.29% |
| 2024 Q2 | 650.69 Thousand USD | -7279.32% |
| 2023 Q2 | 6210.00 USD | 113.5% |
| 2023 Q1 | -45.99 Thousand USD | -308.8% |
| 2023 Q4 | -205.31 Thousand USD | -4.64% |
| 2023 FY | - USD | 2.43% |
| 2023 Q3 | -196.2 Thousand USD | -3259.42% |
| 2022 Q1 | -109.09 Thousand USD | 90.59% |
| 2022 FY | - USD | 68.95% |
| 2022 Q4 | -11.25 Thousand USD | -118.85% |
| 2022 Q3 | 59.67 Thousand USD | 117.62% |
| 2022 Q2 | -338.59 Thousand USD | -210.38% |
| 2021 Q4 | -1.15 Million USD | -1417.09% |
| 2021 Q3 | -76.38 Thousand USD | -4673.65% |
| 2021 Q2 | 1670.00 USD | 102.13% |
| 2021 Q1 | -78.57 Thousand USD | -3732.68% |
| 2021 FY | - USD | -1381.39% |
| 2020 Q3 | -35.59 USD | 0.0% |
| 2020 FY | - USD | 99.58% |
| 2020 Q4 | -2050.00 USD | -5660.04% |
| 2019 FY | - USD | -4515.46% |
| 2018 FY | - USD | 17.14% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2011 Q1 | -196.83 Thousand USD | 79.28% |
| 2010 Q1 | -163.42 Thousand USD | -121.97% |
| 2010 Q2 | -136.47 Thousand USD | 16.49% |
| 2010 Q3 | -240.17 Thousand USD | -75.98% |
| 2010 Q4 | -949.8 Thousand USD | -295.47% |
| 2010 FY | - USD | -823.51% |
| 2009 Q2 | -110.66 Thousand USD | -276.85% |
| 2009 FY | - USD | -136.76% |
| 2009 Q4 | -73.62 Thousand USD | -253.01% |
| 2009 Q3 | 48.11 Thousand USD | 143.48% |
| 2009 Q1 | -29.36 Thousand USD | -106.04% |
| 2008 Q4 | 486.46 Thousand USD | 18467.29% |
| 2008 FY | - USD | 137.14% |
| 2008 Q3 | 2620.00 USD | 104.14% |
| 2008 Q2 | -63.33 Thousand USD | 88.85% |
| 2008 Q1 | -568.13 Thousand USD | 15.91% |
| 2007 Q1 | -50.22 Thousand USD | 0.0% |
| 2007 Q2 | -180.86 Thousand USD | -260.14% |
| 2007 Q3 | -271.73 Thousand USD | -50.25% |
| 2007 Q4 | -675.61 Thousand USD | -148.63% |
| 2007 FY | - USD | -2640.28% |
| 2006 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.11% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 89.334% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.014% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 96.359% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.672% |
| Mesoblast Limited | -62.38 Million USD | 98.986% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 58.829% |
| Genus plc | 73.7 Million USD | 100.858% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 90.435% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 82.171% |
| Marizyme, Inc. | -34.28 Million USD | 98.155% |
| ContraFect Corporation | -64.99 Million USD | 99.027% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 92.791% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 86.028% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 54.886% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 76.086% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 72.786% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -22.075% |
| Accustem Sciences Inc. | -3.74 Million USD | 83.12% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 98.689% |
| EV Biologics, Inc. | -1.26 Million USD | 50.092% |
| Q BioMed Inc. | -617.62 Thousand USD | -2.393% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 117.705% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 72.317% |
| Biomind Labs Inc. | -1.03 Million USD | 38.871% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 106.403% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 91.169% |
| Skye Bioscience, Inc. | -13.54 Million USD | 95.332% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 57.483% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -2429.624% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 83.719% |
| IMV Inc. | -35.52 Million USD | 98.22% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 96.015% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 74.724% |
| GB Sciences, Inc. | -1.41 Million USD | 55.461% |
| Alpha Cognition Inc. | -9.7 Million USD | 93.484% |
| HST Global, Inc. | -5303.00 USD | -11825.438% |
| CSL Limited | 4.78 Billion USD | 100.013% |
| Halberd Corporation | -74.27 Thousand USD | -751.393% |
| Enzolytics Inc. | -2.12 Million USD | 70.198% |
| Resverlogix Corp. | -11.74 Million USD | 94.614% |
| Affymax, Inc. | -14.29 Million USD | 95.576% |
| SYBLEU INC | -141.57 Thousand USD | -346.706% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 79.353% |
| argenx SE | -216.02 Million USD | 99.707% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 98.857% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 151.964% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 57.809% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 266.93% |
| AVAX Technologies, Inc. | -6.11 Million USD | 89.654% |
| Zenith Capital Corp. | -8.6 Million USD | 92.652% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.746% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3530.136% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 74.15% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -259.272% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 98.405% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 78.135% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 39.559% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 9505.205% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 63.862% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 67.078% |
| BioStem Technologies, Inc. | -7.55 Million USD | 91.628% |
| ONE Bio Corp. | 13.61 Million USD | 104.646% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -249.226% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 69.256% |
| Agentix Corp. | -1.37 Million USD | 53.898% |
| LadRx Corporation | 412.28 Thousand USD | 253.391% |
| Cell Source, Inc. | -4.27 Million USD | 85.198% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -72.214% |
| Regen BioPharma, Inc. | 1.46 Million USD | 143.139% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 32.504% |
| NovAccess Global Inc. | -1.03 Million USD | 38.886% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 107.143% |
| Itoco Inc. | -1.86 Million USD | 66.163% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -66.589% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 43.333% |
| Kadimastem Ltd | -2.62 Million USD | 75.903% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -164.439% |
| CytoDyn Inc. | -18.02 Million USD | 96.492% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -700.22% |
| Mobile Lads Corp. | -2.24 Million USD | 71.782% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -5071.363% |
| Qrons Inc. | -40.08 Thousand USD | -1477.82% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -30.211% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 219.903% |
| Rebus Holdings, Inc. | -951 Thousand USD | 33.501% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 40.452% |
| International Stem Cell Corporation | 202 Thousand USD | 413.072% |
| Bioxytran, Inc. | -3.82 Million USD | 83.446% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1101.379% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 74.313% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 98.237% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -1305.347% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 76.903% |
| Neutra Corp. | -181.24 Thousand USD | -248.919% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 96.863% |
| PureTech Health plc | -11.62 Million USD | 94.561% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 96.863% |
| IXICO plc | -707 Thousand USD | 10.551% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 91.771% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 98.692% |
| CSL Limited | 4.73 Billion USD | 100.013% |
| Cellectis S.A. | -92.63 Million USD | 99.317% |